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OBJECTIVE—Synthetic ligands for peroxisome proliferator–
activated receptor- (PPAR-) improve insulin sensitivity in
obesity, but it is still unclear whether inﬂammatory signals
modulate their metabolic actions. In this study, we tested
whether targeted disruption of inducible nitric oxide (NO) syn-
thase (iNOS), a key inﬂammatory mediator in obesity, modulates
the metabolic effects of rosiglitazone in obese mice.
RESEARCH DESIGN AND METHODS—iNOS
/ and
iNOS
/ were subjected to a high-fat diet or standard diet for 18
weeks and were then treated with rosiglitazone for 2 weeks.
Whole-body insulin sensitivity and glucose tolerance were deter-
mined and metabolic tissues harvested to assess activation of
insulin and AMP-activated protein kinase (AMPK) signaling
pathways and the levels of inﬂammatory mediators.
RESULTS—Rosiglitazone was found to similarly improve
whole-body insulin sensitivity and insulin signaling to Akt/PKB in
skeletal muscle of obese iNOS
/ and obese iNOS
/ mice.
However, rosiglitazone further improved glucose tolerance and
liver insulin signaling only in obese mice lacking iNOS. This
genotype-speciﬁc effect of rosiglitazone on glucose tolerance was
linked to a markedly increased ability of the drug to raise plasma
adiponectin levels. Accordingly, rosiglitazone increased AMPK
activation in muscle and liver only in obese iNOS
/ mice.
PPAR- transcriptional activity was increased in adipose tissue
of iNOS
/ mice. Conversely, treatment of 3T3-L1 adipocytes
with a NO donor blunted PPAR- activity.
CONCLUSIONS—Our results identify the iNOS/NO pathway as
a critical modulator of PPAR- activation and circulating adi-
ponectin levels and show that invalidation of this key inﬂamma-
tory mediator improves the efﬁcacy of PPAR- agonism in an
animal model of obesity and insulin resistance. Diabetes 57:
1999–2011, 2008
P
eroxisome proliferator–activated receptor-
(PPAR-) is a member of the ligand-activated
nuclear receptor family, which is highly ex-
pressed in adipose tissues, where it promotes
adipocyte differentiation and lipid storage. PPAR- can be
activated by several endogenous lipid ligands and is a
known target of the antidiabetic agents thiazolidinediones
(1). Thiazolidinediones are known for their lipid-lowering
and insulin-sensitizing actions and are currently used to
manage obesity-linked insulin resistance and type 2 diabe-
tes (2). Although the molecular mechanism of action of
thiazolidinedione/PPAR- ligands on glucose and lipid
metabolism is not fully understood, their ability to in-
crease plasma levels of adiponectin, an adipose-speciﬁc
secretory protein, is thought to be involved in their meta-
bolic and insulin-sensitizing actions (3–5). Adiponectin
circulates as both a hexamer and a high–molecular weight
oligomer. The latter complex form mediates the effects of
thiazolidinediones on insulin sensitivity, particularly on
hepatic glucose production (5–8). The insulin-sensitizing
activity of adiponectin appears to involve the activation of
AMP-activated protein kinase (AMPK) (4,6), a metabolic
sensor that has been reported to alleviate obesity-driven
insulin resistance through metabolic and gene expression
effects (9).
Anti-inﬂammatory mechanisms may also contribute to
the beneﬁcial action of PPAR- activation on insulin
sensitivity. Obesity is a state of abnormal inﬂammatory
response, leading to increased production of proinﬂam-
matory cytokines, which are thought to promote insulin
resistance in key metabolic tissues (10,11). Activation of
PPAR- opposes the effects of proinﬂammatory cyto-
kines, such as tumor necrosis factor- (TNF-), and
negatively interferes with cytokine-inducible transcrip-
tional pathways (e.g., nuclear factor-B [NF-B], signal
transducer and activator of transcription [STAT], and
activator protein 1 [AP-1]) in adipocytes, macrophages,
and other vascular wall cell types (12–15). Thiazo-
lidinediones inhibit the expression of inducible nitric
oxide (NO) synthase (iNOS), a key inﬂammatory medi-
ator in several cell types and tissues (16,17). iNOS
expression is increased in insulin-target tissues and
pancreatic islets of animal models of dietary and genetic
obesity (18–20). We have previously reported that
proinﬂammatory cytokines and the endotoxin lipopoly-
saccharide (LPS) induce iNOS expression and marked
NO production in L6 myocytes and isolated rat skeletal
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DIABETES, VOL. 57, AUGUST 2008 1999muscles, leading to defective insulin stimulation of
glucose transport (21,22). A key role for iNOS in the
pathogenesis of obesity-linked insulin resistance is sup-
ported by our previous observations that targeted dis-
ruption of iNOS protects against muscle insulin
resistance and improves whole-body insulin action in
high-fat–fed obese mice (18). More recently, iNOS dis-
ruption was also found to protect against the adverse
effects of high-fat feeding on vascular insulin resistance (23)
and to reduce insulin resistance in genetically obese ob/ob
mice (24,25). Furthermore, iNOS is induced in skeletal
muscle and adipose tissues of type 2 diabetic subjects
(26,27) where its expression correlates with the occur-
rence of insulin resistance (27) and obesity (26).
Whereas thiazolidinedione-mediated PPAR- activation
reduces iNOS expression in several tissues, there is also
evidence suggesting that activation of the iNOS/NO path-
way can blunt PPAR- activation. Shibuya et al. (28) have
shown that peroxynitrite, an oxidative NO derivative,
inhibits ligand-dependent nuclear translocation of PPAR-
in macrophages, possibly through peroxynitrite-mediated
nitration of PPAR-. This suggests that the iNOS/NO
pathway modulates PPAR- activity, at least in myeloid
cells. However, the potential role of the iNOS/NO pathway
in the modulation of thiazolidinedione/PPAR- action in
key insulin-target tissues of an animal model of obesity
and iNOS induction has not yet been investigated. Here,
we have tested the hypothesis that iNOS modulates
PPAR- activity in insulin-target tissues by investigating
the metabolic and glucoregulatory effects of the thiazo-
lidinedione rosiglitazone in both wild-type and iNOS-
deﬁcient obese mice. The results identify iNOS as a critical
modulator of thiazolidinedione actions in obesity.
RESEARCH DESIGN AND METHODS
Antibodies. Rabbit polyclonal antibodies against P-Ser473 Akt, P-Ser79
acetyl-CoA carboxylase (ACC), and P-Thr172-AMPK were purchased from
Cell Signaling Technology (Beverly, MA) and were used at a 1:500, 1:1,000, and
1:1,000 dilution, respectively. Rabbit polyclonal iNOS, p85, and IRS-2 antibod-
ies and rabbit monoclonal P-Ser82-PPAR- antibody were purchased from
Upstate Biotechnology (Lake Placid, NY) and were used at a 1:500, 1:1,000,
1:1,000, and 1:1,000 dilution, respectively. Rabbit polyclonal adiponectin
antibody was used as previously described (4,29). Mouse monoclonal PPAR-
and P-Tyr (PY20) antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA) and used at a 1:1,000 dilution. Mouse monoclonal -tubulin
antibody was from Sigma (St. Louis, MO). Rabbit anti-RFP antibody (Rock-
land, Gilbertsville, PA) was used at 1:10,000. Goat anti-mouse IgG and goat
anti-rabbit IgG secondary antibodies were purchased from GE Healthcare
(Baie d’Urfe ´, Quebec, Canada) and used at a 1:10,000 dilution.
Animals and treatment. This study was approved by the Animal Care and
Handling Committee of Laval University. Breeding pairs of iNOS wild-type
mice (C57BL/6J) and iNOS knockout mice (C57BL/6-NOS2
tm1Lau) were pur-
chased from The Jackson Laboratories (Bar Harbor, ME). Four-week-old mice
were fed either a ground autoclaved standard chow diet (Sterilizable Global
Rodent; Harlan Teklad, Madison, WI) or an irradiated high-fat diet (55% of
calories derived from fat) (Mouse 9F; Test Diet, Oakville, Ontario, Canada) for
18 weeks. Half of the mice in each dietary cohort were then randomly assigned
to a 15-day treatment with rosiglitazone (30 mg/kg diet as a food admixture;
Avandia; GlaxoSmithKline), corresponding to 0.1 mg  mouse
1  day
1. This
dose of rosiglitazone is relatively low compared with most studies (0.4–3
mg/day) because it was designed to test for potential sensitization of rosiglita-
zone effects by iNOS gene disruption.
Glucose and insulin tolerance test. Twelve days after the beginning of
rosiglitazone treatment, mice were fasted at 8:00 A.M. for 5 h and were injected
with 1 g/kg i.p. glucose or 1.5 units/kg i.p. regular human insulin (Humulin R;
Lilly). Blood samples were collected from the tail vein at time 0 (before
injection), 15, 30, 60, and 90 min after glucose or insulin injection, and blood
glucose level was estimated with an Elite glucometer (Bayer, Etobicoke,
Ontario, Canada).
Indirect calorimetry and body composition determinations. Randomly
selected mice of each group (n  6 per group) in a subset were individually
monitored to determine oxygen consumption (VO2), carbon dioxide produc-
tion (VcO2), and the respiratory quotient by indirect calorimetry. Mice were
initially placed in their individual metabolic cage for 2 days before the
beginning of the experiment. Measurements were made continuously during
the following 2 days (36 measurements  mouse
1  day
1) in an open circuit
system with an oxygen analyzer (S-3A1; Applied Electrochemistry) and a
carbon dioxide analyzer (CD-3A; Applied Electrochemistry). Data presented
are the average of all measurements made over 2 days of monitoring. Dual
X-ray absorptiometry (Piximus; Lunar, Madison, WI) was used to measure
total fat and lean masses in mice anesthetized with isoﬂurane.
Acute insulin injection and death. Mice were anesthetized with isoﬂurane,
and blood sampling (150–200 l) from the orbital sinus was performed for
later plasma analysis. An acute injection of 3.8 units/kg i.v. insulin (Humulin R;
Lilly) was then performed in the tail vein, and mice were killed by decapitation
4 min after injection. Tissues were then rapidly excised and frozen in liquid
nitrogen. Blood was collected and centrifuged at 3,000g for 10 min at 4°C to
isolate plasma. Plasma and tissues were stored at 80°C until biochemical
analysis.
Islet isolation and insulin secretion measurements. Pancreatic islets
were harvested and cultured for 2 h before initiating insulin secretion as
described previously (30). Brieﬂy, islets were distributed in batches of 10 with
four replicates for each condition per genotype. Islets were washed and
preincubated for 45 min at 37°C in Krebs-Ringer bicarbonate buffer containing
10 mmol/l HEPES (KRBH, pH 7.4) with 0.5% defatted BSA (Sigma) and 3
mmol/l glucose. The islets were then incubated for1ha t37°C in KRBH
containing 3, 8, or 16 mmol/l glucose and 0.5% BSA. Some experiments were
also performed in the absence or presence of 0.4 mmol/l palmitate during the
incubation. At the end of the incubation, media were withdrawn for insulin
determination, and islets were harvested for assessment of total insulin
content (30).
Adipose tissue histology. Tissues were ﬁxed in 10% buffered formalin and
embedded in parafﬁn. Multiple 10-m sections were obtained from epididymal
white adipose tissue (WAT) and stained with hematoxylin-eosin. Images were
acquired using a BX60 microscope (Olympus, NY) and an RT slider 2.3.0
camera (Diagnostic Instrument, Sterling Heights, MI) and were analyzed using
SPOT 4.0.2 software. For each group (n  6), at least four ﬁelds, representing
300 adipocytes per slide, were analyzed, and the geometric mean of adipocyte
diameter was calculated to estimate adipocyte mass. Cellularity was calcu-
lated as the ratio of epididymal tissue mass to mean adipocyte mass.
RNA extraction and RT-PCR. Fifty milligrams of WAT was used to isolate
total RNA using Trizol reagent (Invitrogen), and iNOS and -actin mRNAs
were measured by semiquantitative RT-PCR (18,21). For PCR, 50 ng each of
the following primer pairs was used: iNOS, 5	-CAG CCT CAG AGT CCT TCA
TG-3	 (forward) and 5	-GGT GCT TGC CTT ATA CTG GTC-3	 (reverse); and
-actin, 5	-TCA CCC ACA CTG TGC CCA TCT ACG A-3	 (forward) and 5	-GGA
TGC CAC AGG ATT CCA TAC CCA-3	 (reverse). Ampliﬁcation products were
run in 8% acrylamide gel or 1.5% agarose gel containing 1 g/ml ethidium
bromide and analyzed under UV illumination.
Protein extraction, immunoprecipitation, and Western blotting. Fifty
milligrams of quadriceps muscle, WAT, and liver tissues were pulverized with
a pestle and mortar in liquid nitrogen, and the powder was homogenized in 6
vol (muscle and liver) or 4 vol (WAT) homogenization buffer (20 mmol/l
Tris-HCl, pH 7.5, 150 mmol/l NaCl, 1 mmol/l CaCl2, 1 mmol/l MgCl2, 10%
glycerol, 1% Igepal CA-630, 10 mmol/l NaF, 2 mmol/l Na3VO4, 1 mmol/l
phenylmethylsulfonyl ﬂuoride, and protease inhibitors). One milligram of
proteins was immunoprecipitated overnight at 4°C with 2 g PY20. Immune
complexes were washed three times with PBS containing 1% Nonidet P-40, 10
mmol/l NaF, 2 mmol/l Na3VO4, and protease inhibitors. For Western blot
analysis, 10–50 g crude protein lysates or immune complexes were solubi-
lized in sample buffer, loaded on a 7.5% acrylamide gel and subjected to
SDS-PAGE and Western blotting as previously described (21,22). Bands were
detected by standard chemiluminescence (Perkin Elmer) and were scanned
for quantiﬁcation using Image J software. Adipose tissue lysates were
analyzed for TNF- and interleukin-6 (IL-6) content using a murine ELISA kit
(BD Biosciences, Mississauga, Ontario, Canada).
Plasma hormones and adipokines. Plasma leptin, insulin, adiponectin, and
resistin levels were determined using mouse radioimmunoassay kits as
recommended by the manufacturer (Linco Research, St. Charles, MO). Insulin
levels during glucose tolerance test (GTT) were determined using a mammal
ELISA kit (Alpco Diagnostics, Salem, NH). Different molecular weight adi-
ponectin complexes were separated by velocity sedimentation/gel ﬁltration
chromatography as previously described (5,7).
PPAR- expression, phosphorylation, and transcriptional activity.
3T3-L1 cells, provided by Dr. A. Klip (Hopsital for Sick Children, Toronto,
Canada) were grown and differentiated as previously described (17). Fully
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2000 DIABETES, VOL. 57, AUGUST 2008differentiated 3T3-L1 adipocytes were treated with sodium nitroprusside
(Sigma) or peroxynitrite (Upstate) for 24 h. Cell culture supernatants were
collected, and nitrite levels were determined as an indirect measurement
of NO production by the Griess method (17,21,22). Cell lysates were used
for determination of PPAR- expression and Ser-82 phosphorylation.
Nuclear extracts were prepared, and 10 l was analyzed for PPAR--
speciﬁc transcription factor binding activity as described by the manufac-
turer (Cayman, Ann Arbor, MI). In brief, nuclear extracts were loaded on
a 96-well plate coated with a double-stranded DNA sequence containing
the peroxisome proliferator response element. After 16-h incubation at
4°C, the plates were washed, and a primary antibody directed against
PPAR- was added for1ha troom temperature. A secondary antibody
conjugated to horseradish peroxidase was added to provide a sensitive
colorometric readout at 450 nm. The results were corrected for total
protein content in 10 l nuclear extract. HEK293T cells were provided by Dr.
J. Lavoie (Centre de Recherche en Cance ´rologie, Que ´bec, Canada). The cells
were transfected with mouse PPAR-2 and pGL3-PPRE (provided by Dr. F.
Picard, Hopital Laval, Que ´bec, Canada) and pmRFP-N1 (provided by Dr. J.
Lavoie) using calcium phosphate. Twenty-four hours after transfection, cells
were treated with sodium nitroprusside or peroxynitrite for 8 h followed by
addition of 20 mol/l troglitazone for 16 h. Cell lysates were analyzed for
luciferase activity and corrected for expression of RFP by Western blot by
scanning and quantiﬁcation.
Data presentation and statistical analysis. Data are expressed as means 

SE. Except for basal physiological parameters, only data from the high-fat diet
cohorts and the chow-fed untreated iNOS
/ group (used as a reference) are
shown in the ﬁgures, because iNOS gene disruption and rosiglitazone treat-
ments had only marginal effects in the chow-fed groups. The main effect of
diet on all parameters were analyzed by a 2  2  2 factorial ANOVA test. The
main and interactive effects of genotype (iNOS
/, iNOS
/) and treatment
(untreated, rosiglitazone) were analyzed separately for each dietary cohort by
a2 2 factorial ANOVA test. All parameters of each dietary cohort were also
analyzed separately by ANOVA. Pairwise between-group differences were
identiﬁed in the high-fat–fed cohort by post hoc Fisher’s protected least
signiﬁcant difference test. Results of the latter analysis in the high-fat–fed
cohort are presented at the end of each ﬁgure legend. The level of signiﬁcance
was chosen as P  0.05.
RESULTS
Effects of genotype, high-fat feeding, and rosiglita-
zone on physiological parameters. iNOS
/ and
iNOS
/ mice were fed a standard low-fat chow diet or a
high-fat diet for 18 weeks to induce obesity and insulin
resistance. Half of the mice of each dietary cohort were
then treated with rosiglitazone for 15 days. High-fat–fed
mice of either genotype showed a similar increase in total
body weight, body weight gain, and total body fat mass,
and rosiglitazone treatment did not affect these parame-
ters (Table 1). The daily caloric intake of high-fat–fed mice
was, as expected, higher than that of chow-fed mice. A
small increase in caloric intake was also observed in iNOS
knockout mice (P  0.03 for genotype effect), but food
consumption was similar between iNOS
/ and iNOS
/
mice during rosiglitazone treatment (Table 1).
Rosiglitazone inhibits iNOS induction in adipose tis-
sue of obese high-fat–fed mice. We have previously
shown that iNOS is induced in high-fat–fed obese mice
(18). iNOS induction in WAT of high-fat–fed mice was
conﬁrmed by RT-PCR and Western blot analysis of WAT
(Fig. 1). We found that both iNOS mRNA and protein levels
were increased two- to threefold (P  0.05) in WAT of
obese iNOS
/ mice compared with control chow-fed
mice. Rosiglitazone treatment completely normalized
iNOS expression levels to those observed in chow-fed
mice. As expected, iNOS expression was not detected in
WAT of iNOS
/ mice.
iNOS disruption sensitizes obese mice to the beneﬁ-
cial effect of rosiglitazone on glucose tolerance. After
18 weeks of high-fat feeding, fasting blood glucose and
insulin levels were increased in both obese iNOS
/ and
iNOS
/ mice compared with their lean chow-fed coun-
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DIABETES, VOL. 57, AUGUST 2008 2001terparts (Table 1). Rosiglitazone was found to reduce
hyperglycemia in obese mice of both genotypes. Hyperin-
sulinemia was decreased by rosiglitazone in obese
iNOS
/, but not in obese iNOS
/ mice, because iNOS
disruption per se tended to reduce insulin levels (P 
0.08). A signiﬁcant effect of iNOS gene disruption was also
observed on plasma leptin and triglyceride levels (2  2
ANOVA test).
The effect of rosiglitazone on whole-body insulin sensi-
tivity and glucose tolerance was next examined in both
genotypes. High-fat feeding caused insulin resistance and
glucose intolerance in obese iNOS
/ mice compared with
lean chow-fed iNOS
/ mice (Fig. 2A–D). Insulin sensitiv-
ity was independently improved by both iNOS disruption
and rosiglitazone treatment as revealed by insulin toler-
ance curves (Fig. 2A) and the average reduction in blood
glucose 15 min after insulin injection (Fig. 2B). Rosiglita-
zone failed to further enhance insulin sensitivity in obese
iNOS
/ mice. In contrast, neither iNOS disruption nor
rosiglitazone treatment alone was found to protect mice
from high-fat diet–induced glucose intolerance (Fig. 2C
and D). However, rosiglitazone markedly improved glu-
cose tolerance in obese mice lacking iNOS (Fig. 2C and D).
Insulin levels during the GTT was elevated in high-fat–fed
iNOS
/ and iNOS
/ mice compared with the chow-fed
group (Fig. 2E). Rosiglitazone reduced insulin levels (P 
0.05) but not when combined with iNOS gene disruption.
Glucose-stimulated insulin secretion (GSIS) in freshly
isolated islets was increased (P  0.05) in high-fat–fed
obese iNOS
/ mice compared with islets from lean chow-
fed iNOS
/ mice (Fig. 2F). This effect was only observed
at the highest dose of glucose tested. GSIS was affected
neither by iNOS genetic deletion nor by rosiglitazone
treatment. GSIS by isolated islets was also similar in the
presence of palmitate during the incubations (data not
shown).
iNOS disruption increases insulin signaling to Akt/
PKB in liver of rosiglitazone-treated obese mice. The
effect of rosiglitazone on insulin action in skeletal muscle
and liver of iNOS
/ and iNOS
/ mice was then assessed
by measurement of insulin-mediated Ser-473 phosphoryla-
tion of Akt/PKB, a key effector of insulin-induced inhibi-
tion of hepatic glucose production and stimulation of
muscle glucose uptake (31). As depicted in Fig. 3, high-fat
feeding caused a profound insulin resistance in muscle
(Fig. 3A) and liver (Fig. 3B), as demonstrated by a 50 and
75% reduction in insulin-stimulated Akt/PKB phosphoryla-
tion, respectively, compared with the effect of insulin in
chow-fed mice (dashed lines). As previously observed for
whole-body insulin sensitivity (insulin tolerance test), rosi-
glitazone treatment and iNOS deﬁciency both indepen-
dently corrected defective insulin-induced Akt/PKB
activation in muscle, but their combination did not further
increase insulin action in that tissue (Fig. 3A). Conversely,
in liver, neither rosiglitazone nor iNOS gene disruption
alone was found to improve insulin-stimulated Akt/PKB
phosphorylation, whereas rosiglitazone treatment in obese
iNOS
/ markedly enhanced the ability of insulin to
phosphorylate the enzyme (Fig. 3B). Similar data were
obtained when assessing more proximal insulin-signaling
events, such as insulin-induced p85 binding to tyrosine-
phosphorylated IRS-1/2 in muscle and liver and IRS-2
tyrosine phosphorylation in liver (Supplementary Fig. 1,
which is detailed in the online appendix [available at
http://www.dx.doi.org/10.2337/db08-0540]).
iNOS disruption increases the ability of rosiglitazone
to raise plasma adiponectin levels in obese mice.
Thiazolidinediones are known to exert their beneﬁcial
effects largely by increasing adiponectin circulating con-
centrations (4,6). We thus next examined whether iNOS
disruption modulates the ability of rosiglitazone to in-
crease plasma adiponectin concentration in obese mice.
As shown in Fig. 4A, rosiglitazone treatment induced a
2.9-fold increase in total plasma adiponectin levels in
obese iNOS
/ compared with untreated obese iNOS
/
mice. A similar effect of the thiazolidinedione was ob-
served in chow-fed control mice (data not shown). Re-
markably, the effect of rosiglitazone on adiponectin levels
was markedly enhanced in obese iNOS
/ mice relative to
obese iNOS
/ mice, as reﬂected by the 5.6-fold increase
in the adipokine plasma concentrations after thiazo-
lidinedione treatment in the former group. Resistin plasma
levels were also measured but found not to be affected by
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Fig. 2A).
Because complex distribution, not the absolute amounts
of adiponectin, correlates with thiazolidinedione-mediated
improvement in insulin sensitivity (7), we next evaluated
the effect of rosiglitazone on the formation of high–
molecular weight complexes of adiponectin in wild-type
and iNOS-deﬁcient animals. Obesity in both genotypes had
no effect on basal high–molecular weight adiponectin
plasma levels compared with lean control mice (Fig. 4A,
dashed line). Rosiglitazone barely increased high–molecu-
lar weight adiponectin in iNOS
/ mice, but the thiazo-
lidinedione was much more potent in iNOS
/ mice,
increasing high–molecular weight adiponectin levels by
8.2-fold in these mice.
Rosiglitazone induces adipose tissue remodeling in
obese mice lacking iNOS. Because adiponectin secretion
is greater in newly differentiated small adipocytes, we next
explored the possibility that rosiglitazone exerted a geno-
type-speciﬁc effect on adipose tissue remodeling. Histolog-
ical analysis showed that rosiglitazone, at the low dose
used, failed to signiﬁcantly affect adipocyte size or number
in obese iNOS
/ mice (Fig. 4B). In marked contrast, the
thiazolidinedione clearly induced adipose tissue remodel-
ing in obese iNOS
/ mice, which was characterized by
the presence of an increased number (75%, P  0.05) of
smaller (45%, P  0.05) adipocytes compared with
untreated obese iNOS
/ mice.
Adipose tissue levels of both TNF- and IL-6 were
increased by high-fat feeding in both genotypes (Supple-
mentary Fig. 2B and C). Moreover, TNF- was slightly
increased by rosiglitazone treatment in obese wild-type
mice. Interestingly, the effect of rosiglitazone on adipose
TNF- levels was not observed in iNOS
/ mice, suggest-
ing that iNOS may be needed for this action. No effect of
the genotype was observed on adipose IL-6 levels.
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in rosiglitazone-treated obese iNOS
/ mice. Because
adiponectin activates AMPK in several tissues (32,33), we
next determined whether elevation of circulating adi-
ponectin in response to rosiglitazone is associated with
AMPK activation in insulin-target tissues. Both phosphor-
ylation of AMPK on Thr172 and of ACC on Ser-79, a
well-established downstream target of AMPK activation
(34), were determined (Fig. 5A–C). Activation of the
AMPK pathway was found to be reduced in muscle, liver,
and WAT of high-fat–fed obese iNOS
/ mice compared
with lean chow-fed iNOS
/ mice (Fig. 5A–C, dashed
lines). At the low dose used, rosiglitazone treatment of
obese iNOS
/ mice improved ACC phosphorylation in
WAT but not in muscle and liver. However, the thiazo-
lidinedione markedly improved ACC phosphorylation in
muscle, liver, and WAT of mice lacking iNOS. Interest-
ingly, the enhanced ACC phosphorylation in both liver and
fat (but not in muscle) was at least partly accounted for by
an increased expression of ACC, especially in iNOS
/
tissues. This effect of rosiglitazone to increase ACC pro-
tein levels has been recently reported in adipose tissue of
high-fat–fed rats (35). Because AMPK activation switches
on catabolic pathways and increases energy expenditure,
we next determined whether enhanced activation of this
pathway in rosiglitazone-treated obese iNOS
/ led to
increased whole-body energy expenditure as measured by
indirect calorimetry. As depicted in Fig. 5D, total energy
expenditure was similar in untreated obese iNOS
/ and
obese iNOS
/ mice. However, energy expenditure was
signiﬁcantly increased in obese iNOS
/ mice treated with
rosiglitazone. The respiratory quotient was reduced in all
high-fat–fed groups compared with chow-fed iNOS
/
animals (Fig. 5D), consistent with increased consumption
of dietary lipids. On the other hand, neither iNOS gene
disruption nor rosiglitazone treatment of high-fat–fed
obese mice affected the respiratory quotient, indicating
that fat remained the principal substrate source in all
groups consuming the high-fat diet.
iNOS inhibits PPAR- activity in adipose tissue and
adipocytes. Because rosiglitazone action was potentiated
in mice with iNOS gene disruption, we next tested whether
PPAR- activation was affected by the genotype. PPAR-
expression was increased in chow-fed iNOS
/ mice com-
pared with their wild-type controls (Fig. 6A). This geno-
type effect was not observed in the high-fat–fed mice. We
also assessed PPAR- phosphorylation on Ser-82/112,
which is associated with decreased transcriptional activity
(36,37). We found that PPAR- phosphorylation on Ser-
82/112, corrected for the PPAR- protein abundance in
the sample, was signiﬁcantly reduced in adipose tissue
of both chow- and high-fat–fed iNOS
/ mice compared
with iNOS
/ counterparts. This effect was similar for
PPAR-1 (Ser-82) and PPAR-2 (Ser-112) isoforms,
which are both expressed in adipose tissue. This sug-
gests that lack of iNOS increases PPAR- transcriptional
activity in adipose tissue. To more directly test this
hypothesis, we next determined the effect of NO on
PPAR- in cultured adipocytes. Differentiated 3T3-L1
adipocytes were exposed to increasing concentrations
of the NO donor sodium nitroprusside for 24 h, and
PPAR- expression and phosphorylation were assessed
by Western blot analysis (Fig. 6B). These experiments
revealed that sodium nitroprusside reduces the expres-
sion of PPAR- (both 1 and 2 isoforms). Furthermore,
the ratio of Ser-82/112 phosphorylated PPAR- over
total PPAR- protein was increased, suggesting that
sodium nitroprusside blunts PPAR- transcriptional ac-
tivity both by lowering its expression and increasing its
inhibitory phosphorylation. Interestingly, these effects
were not observed on exposing cells to the NO deriva-
tive peroxynitrite. To more directly test whether NO
inhibits PPAR- transcriptional activity, we prepared
nuclear extracts from these cells to assess PPAR-
transcription factor binding (Fig. 6C). We also trans-
fected HEK293T cells with a PPAR- reporter (pGL3-
PPRE) and looked at its troglitazone-induced activity
after treatment with the NO donor sodium nitroprusside
or peroxynitrite (Fig. 6D). These experiments revealed
that sodium nitroprusside causes a dose-dependent
inhibition of both PPAR- binding and thiazolidinedi-
one-induced activity, conﬁrming that NO but not per-
oxynitrite blunts PPAR- transcriptional activity in
adipocytes.
DISCUSSION
PPAR- agonists, such as thiazolidinediones, are known
for their antidiabetic and insulin-sensitizing properties.
Rosiglitazone and pioglitazone are two clinically approved
thiazolidinediones for the management of obesity-linked
type 2 diabetes, but some side effects are associated with
their use. Treatment with thiazolidinediones is usually
correlated with increased body weight gain due to differ-
entiation of fat cells and ﬂuid retention caused by accel-
erated sodium absorption by the collecting duct (38,39).
Thiazolidinedione treatment has also been recently asso-
ciated with increased risk for myocardial infarction and
heart failure (40). This prompts the elaboration of new
PPAR- agonists and the search for novel PPAR- regula-
tory pathways. Here, we show that the iNOS/NO pathway
is a novel and critical modulator of thiazolidinedione/
PPAR- action in an animal model of obesity.
To demonstrate the involvement of the iNOS/NO path-
way in thiazolidinedione action in vivo, we compared the
action of a low dose of rosiglitazone on several glucoregu-
latory and metabolic parameters in wild-type and iNOS
knockout mice rendered obese by feeding a high-fat diet. A
relatively low dose of rosiglitazone (0.1 vs. 0.4–3 mg/day in
most studies [41–44]) and a short duration of treatment
were used to better appreciate the effect of the absence of
iNOS on the metabolic actions of thiazolidinedione. We
found that this low dose of rosiglitazone improves insulin
sensitivity and insulin signaling in muscle but failed to
improve glucose tolerance and liver insulin signaling in
wild-type obese mice. This is consistent with previous
observations showing that muscle insulin sensitivity is
rapidly improved by thiazolidinediones, whereas a longer
duration of treatment is generally required to improve
insulin action in liver (45). Recent studies using tissue-
speciﬁc disruption of PPAR- have dissected out the
contribution of the principal PPAR--expressing tissues to
action of thiazolidinedione. Muscle PPAR- plays a crucial
role in maintaining systemic insulin sensitivity and in
mediating thiazolidinedione action in muscle but not in
liver (46). In contrast, liver PPAR- expression is not
required for thiazolidinedione action (47), but studies
using A-Zip mice lacking adipose tissue showed thiazo-
lidinedione resistance in liver (48). Taken together, these
studies suggest that the beneﬁcial effects of thiazolidinedi-
one on the liver are most likely mediated by adipose tissue,
which predominantly expresses PPAR- (49,50). In agree-
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FIG. 5. Effect of iNOS gene disruption and rosiglitazone treatment on AMPK activation and energy expenditure in high-fat–fed mice.
Phosphorylation of AMP-activated kinase (P-AMPK) and ACC (P-ACC) and total expression were evaluated in quadriceps muscle (A), liver (B),
and WAT (C) by Western blotting. Data are expressed relative to untreated chow-fed iNOS
/ mice values (dashed lines) analyzed on the same
gels. D: Whole-body energy expenditure (top) and respiratory quotient (bottom) were measured by indirect calorimetry. Means  SE of 4–8 mice
per group. *P < 0.05 vs. respective untreated mice, #P < 0.05 vs. respective iNOS
/ mice, †P < 0.05 vs. untreated high-fat–fed iNOS
/ mice.
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Differentiated 3T3-L1 adipocytes were treated with sodium nitroprusside (SNP) or peroxynitrite (PN) at the indicated concentrations for 24 h.
B: Total cellular extracts were analyzed by Western blot for the expression of PPAR- and its phosphorylation on Ser-82/112, as well as tubulin
levels. C: Nuclear extracts were analyzed for PPAR- activity as described in RESEARCH DESIGN AND METHODS. Shown are means  SE of four
determinations in two individual experiments; *P < 0.05 vs. control (CTL) cells. D: Luciferase assays of 293T cells transfected with PPAR-2 and
pGL3-PPRE and treated with sodium nitroprusside or peroxynitrite at the indicated concentration for 24 h. During the last 16 h of treatment, 20
mol/l troglitazone was added. Shown are means  SE of four individual experiments done in triplicate; *P < 0.05, **P < 0.01 vs. control (CTL)
cells. C and D: Supernatants were sampled for nitrite determinations, and values are shown under the graphs.
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of a low dose of rosiglitazone on liver insulin signaling and
glucose tolerance in the present study was associated with
failure of the thiazolidinedione to change adipose tissue
morphology. In sharp contrast, iNOS disruption was found
to sensitize obese mice to the action of rosiglitazone on
glucose tolerance and liver insulin action without any
further effect in muscle. This genotype-speciﬁc action of
thiazolidinedione was linked to fat remodeling in iNOS-
deﬁcient mice as revealed by increased adipose tissue
cellularity, an established indicator of adipose PPAR-
activation (51).
It is well known that PPAR- agonists increase total
plasma adiponectin levels by two- to threefold (3). Adi-
ponectin is thought to be the principal mediator of the
insulin-sensitizing action of PPAR-. Transgene-induced
overexpression of adiponectin, which raises the secretion
of the adipokine in its native oligomeric form by threefold,
was found to induce effects similar to those of a chronic
treatment with PPAR- agonists (4). More direct evidence
for the role of adiponectin in thiazolidinedione action was
recently provided using adiponectin-null mice. The ability
of rosiglitazone to improve glucose tolerance in ob/ob mice
lacking adiponectin is markedly diminished. Furthermore,
rosiglitazone failed to activate AMPK in tissues of adi-
ponectin-null mice (6). Moreover, it has been shown that
the high–molecular weight complex structure of adiponec-
tin is key to its insulin-sensitizing action, particularly in
liver (7,8). These studies showed that only high–molecular
weight adiponectin can reduce blood glucose levels when
injected into adiponectin-deﬁcient mice. Consistent with
these observations, only mice lacking iNOS, which showed
a marked elevation in plasma high–molecular weight adi-
ponectin levels, exhibited improved glucose tolerance and
liver insulin action in response to rosiglitazone, conﬁrming
the high sensitivity of the liver to changes in high–
molecular weight form concentrations (7). Adipose tissue
remodeling caused by rosiglitazone treatment of iNOS
knockout mice likely explains the raised plasma high–
molecular weight adiponectin complexes in these animals
because previous studies reported a strong inverse rela-
tionship between adipose cell size and adiponectin secre-
tion (52,53).
Rosiglitazone treatment increased AMPK activity in fat
but not in muscle and liver of wild-type obese mice, even
though the PPAR- agonist induced a threefold increase in
plasma adiponectin levels. At ﬁrst sight, this may appear
surprising because activation of AMPK by adiponectin is
thought to be involved in its glucose metabolic and insulin-
sensitizing actions (32,33). However, this may be ex-
plained by the failure of rosiglitazone to raise plasma
adiponectin in its high–molecular weight form in wild-type
obese mice. Kobayashi et al. (54) showed that only the
high–molecular weight complex of adiponectin can acti-
vate AMPK in endothelial cells. The lack of effect of
rosiglitazone on high–molecular weight adiponectin secre-
tion could be linked to iNOS induction in these animals
(Fig. 1). We propose that in iNOS-deﬁcient obese mice, the
effects of rosiglitazone on high–molecular weight adi-
ponectin secretion and AMPK activation are unopposed by
iNOS-derived NO, resulting in improved metabolic actions,
as reﬂected by enhanced energy expenditure and de-
creased levels of plasma triglycerides. The ﬁnding of
unaltered respiratory quotient values among the high-fat–
fed obese iNOS
/ and iNOS
/ groups probably reﬂects
the fact that both fat and glucose oxidation are expected
to be increased on marked activation of AMPK in rosiglit-
azone-treated iNOS
/ mice. Hence, our data are consis-
tent with the hypothesis that induction of the iNOS/NO
pathway in adipose tissue of obese mice contributes to
deteriorating hepatic insulin action and glucose tolerance
by interfering with the ability of rosiglitazone to increase
plasma high–molecular weight adiponectin and liver
AMPK activation.
We further explored whether the iNOS/NO pathway
blunts the action of thiazolidinedione by interfering with
PPAR- transcriptional activity. Phosphorylation of
PPAR- on Ser-82/112 is known to suppress its transcrip-
tional activity (36,37). Inhibitory phosphorylation of both
PPAR- isoforms on Ser-82/112 was reduced in adipose
tissue of iNOS
/ mice, whereas treatment of adipocytes
with the NO donor sodium nitroprusside enhanced
PPAR- Ser-82/112 phosphorylation and blunted thiazo-
lidinedione-induced PPAR- reporter activity, consistent
with the hypothesis that iNOS-derived NO represses
PPAR- transcriptional activity. Our data further suggest
that iNOS represses adipose PPAR- expression. This
ﬁnding was not observed in high-fat–fed obese mice
lacking iNOS, suggesting that other factors than NO may
repress PPAR- in adipose tissue of these obese mice.
NO exerts its action in part by inducing posttransla-
tional modiﬁcations of speciﬁc amino acid residues within
target proteins. S-nitrosylation of cysteine residues within
signaling proteins occurs in physiological conditions,
whereas tyrosine nitration is typically associated with
increased generation of the NO derivative peroxynitrite in
oxidative stress–related diseases. Shibuya et al. (28) pre-
viously reported that treatment of macrophages with
inﬂammatory cytokines, LPS, or peroxynitrite increased
tyrosine nitration of PPAR-, resulting in impaired ligand-
dependent nuclear translocation. However, peroxynitrite
failed to reduce PPAR- transcriptional activity in our
adipocyte studies, suggesting that PPAR- regulation may
be differently controlled in adipose versus myeloid cells.
Further studies will be required to identify the mecha-
nism(s) by which NO suppresses PPAR- activity.
We have reported that iNOS induction is repressed after
AMPK activation by PPAR- agonists in 3T3-L1 adipocytes
(17). The present study conﬁrms that this inhibitory effect
of PPAR- on iNOS induction also occurs in fat tissue of
thiazolidinedione-treated obese mice. We hypothesize that
the inhibitory effect of rosiglitazone treatment on iNOS
induction may be linked to its ability to raise adiponectin
levels because the adipokine suppresses cytokine produc-
tion and NF-B transcriptional activation by activated
macrophages (55,56). However, we found that rosiglita-
zone treatment of wild-type mice, despite raising adi-
ponectin levels, failed to reduce IL-6 and in fact slightly
increased TNF- levels in adipose tissue. This intriguing
effect of rosiglitazone has been reported previously (57).
Interestingly, rosiglitazone failed to increase adipose
TNF- levels in iNOS-deﬁcient mice, possibly because the
drug further raised plasma adiponectin concentrations,
particularly in its high–molecular weight form, thus blunt-
ing rosiglitazone effect on TNF- in the latter genotype.
Thus, iNOS inhibition by PPAR- activation is a key
anti-inﬂammatory mechanism that likely contributes to the
beneﬁcial effects of thiazolidinedione in obese mice. This
is exempliﬁed by our data in iNOS-deﬁcient mice where
complete lack of iNOS was found to markedly sensitize
PPAR- agonism in WAT, as reﬂected by adipose tissue
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high–molecular weight form.
Taken together, our results allow the design of a model
that integrates the metabolic and anti-inﬂammatory effects
of thiazolidinedione in obesity, emphasizing the roles of
PPAR-, iNOS, adiponectin, and AMPK (Fig. 7). iNOS is
induced in obesity, which leads to the development of
inﬂammation-mediated insulin resistance in skeletal mus-
cle (18) and reduced action of PPAR- ligands in adipose
tissue. The latter results in reduced adiponectin secretion,
particularly in its high–molecular weight form, and limited
activation of AMPK and tissue insulin signaling, particu-
larly in the liver. Thiazolidinedione increase muscle insulin
action by directly targeting muscle PPAR-. Lack of iNOS
improved insulin sensitivity in muscle but had no effect on
the liver, as we previously reported (18). However, iNOS
disruption sensitizes adipose tissue to PPAR- agonism,
thus raising plasma high–molecular weight adiponectin
levels. This leads to increased AMPK activation in the liver
and improvement of hepatic insulin sensitivity and glucose
tolerance in obese iNOS
/ mice.
The present results have potential clinical relevance.
iNOS might represent a promising therapeutic target to
increase PPAR- agonism in obese insulin-resistant sub-
jects, reducing the effective doses of thiazolidinediones for
improving glucose tolerance. By increasing the efﬁcacy of
thiazolidinediones, iNOS inhibitors might limit the side
effects of these drugs on the renal and cardiovascular
systems. It has been reported that the endothelial hyper-
permeability response to rosiglitazone was most pro-
nounced at concentrations of the thiazolidinedione (10–
100 mol/l) that correspond to the upper range of
therapeutic plasma drug concentrations in routine clinical
practice (58). Thus, combination therapy with a low dose
of thiazolidinedione and iNOS inhibitors may represent a
promising avenue for the treatment of obesity-linked type
2 diabetes.
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